NasdaqGS - Nasdaq Real Time Price USD

Gritstone bio, Inc. (GRTS)

0.7753

-0.0376

(-4.63%)

As of 12:57 PM EDT. Market Open.

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE -- -- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI) -- -- Publication underscores the important role of antigen selection and cassette design in the development of neoan

GlobeNewswire 10 days ago

GRTS
-4.63%
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences. Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: https://ir.gritstonebio.com/investors/events. Archived replays will be

GlobeNewswire 17 days ago

GRTS
-4.63%
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

-- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation and CD4+ immunogenicity over publicly available models -- -- Combined with Gritstone's vaccine vectors, EDGE has demonstrated best-in-class potential in identifying neoantigens capable of eliciting T cell immune responses for robust and durable immunity -- EMERYVILL

GlobeNewswire 17 days ago

GRTS
-4.63%
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deductin

GlobeNewswire 23 days ago

GRTS
-4.63%
Gritstone bio Announces Proposed Public Offering

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the shares of commo

GlobeNewswire 23 days ago

GRTS
-4.63%
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction of progression or death with GRANITE vs. control) in a high-risk group, where clinical data are more mature ([95% CI, 0.15-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response (as defined by protocol) is uninformative due to an unexpectedly persi

GlobeNewswire 23 days ago

GRTS
-4.63%
3 Speculative Stocks You Can Buy for $3 or Less

The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens. Still, analyst-endorsed ideas could put the odds in the gamblers’ favor. Another reason why speculative stocks are so enticing is accessibility. Not all brokerages offer fractional ownership of shares. Therefore, some retail investors may be blocked out of in

InvestorPlace last month

GRTS
-4.63%
Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates

Gritstone bio, Inc. ( NASDAQ:GRTS ) just released its latest yearly results and things are looking bullish. Overall...

Simply Wall St. last month

GRTS
-4.63%
Gritstone bio Full Year 2023 Earnings: Beats Expectations

Gritstone bio ( NASDAQ:GRTS ) Full Year 2023 Results Key Financial Results Revenue: US$16.3m (down 18% from FY 2022...

Simply Wall St. last month

GRTS
-4.63%
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

-- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating GRANITE, Gritstone’s personalized cancer vaccine in front-line metastatic, microsatellite-stable colorectal cancer (MSS-CRC) remain expected in 1Q 2024 -- -- National Cancer Institute-led Phase 1 study evaluating Gritstone's "off-the-shelf" cancer vaccine, SLATE, combined with neoantigen cell therapy expected to begin in the coming months -- -- Gritstone incorporating GMP-grade raw materials in the manufacture of its samRNA v

GlobeNewswire last month

GRTS
-4.63%
Gritstone bio Announces Workforce Reduction

EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced an approximately 40% reduction of its workforce. The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving external funding it previously anticipated beginning in 1Q 2024, associated with the initiation of the study. “The lack

GlobeNewswire last month

GRTS
-4.63%
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it is now preparing to launch the Phase 2b head-to-head trial of its next-generation COVID-19 vaccine in the Fall of 2024 rather than 1Q24. This is to allow use of fully GMP-grade raw materials in the vaccine, which is expected to increase the regulatory utility of the trial. “After recent commun

GlobeNewswire 2 months ago

GRTS
-4.63%
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase an aggregate of 147,000 shares of its common stock with an exercise price of $2.26, which is equal to the closing price of Gritstone’s common stock on February 6, 2024, th

GlobeNewswire 2 months ago

GRTS
-4.63%
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

A company’s size does not necessarily dictate the size of it’s returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will undoubtedly benefit your investments. These penny stocks with potential can be beneficial for generating returns. Let’s analyze the following so you can consider adding them to your portfolio. Asure (ASUR) Source: Shutterstock Asure Software (NASDAQ:ASUR) produces cloud-based software solutions that

InvestorPlace 2 months ago

ASUR

SYRS

GRTS
-4.63%
Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

Gritstone bio, Inc. ( NASDAQ:GRTS ) shareholders will doubtless be very grateful to see the share price up 52% in the...

Simply Wall St. 3 months ago

GRTS
-4.63%
Gritstone bio to Participate in Upcoming Investor Conference

EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conference: B. Riley Securities' 4th Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 18, 2024 at 1:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer A live webcast o

GlobeNewswire 3 months ago

GRTS
-4.63%
Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved Drastically

Celebrations may be in order for Gritstone bio, Inc. ( NASDAQ:GRTS ) shareholders, with the analysts delivering a...

Simply Wall St. 4 months ago

GRTS
-4.63%
Gritstone bio to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: 6th Annual Evercore ISI HealthCONx Conference (Fireside Chat)Presentation Date and Time: Wednesday, November 29, 2023 at 10:00am ETSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation:

GlobeNewswire 5 months ago

GRTS
-4.63%
Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine Development

Advancements in COVID-19 and Cancer Vaccine Programs Amid Increased R&D Spending

GuruFocus.com 5 months ago

GRTS
-4.63%
Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

-- BARDA contract and IDWeek presentations position Gritstone’s self-amplifying mRNA (samRNA) as a leading next-generation approach to COVID-19 prevention; preparations underway for Phase 2b head-to-head study evaluating samRNA candidate versus an approved COVID-19 vaccine -- -- Preliminary data from Phase 2 portion of Phase 2/3 study evaluating Gritstone’s personalized cancer vaccine (PCV), GRANITE, in first-line metastatic, microsatellite stable colorectal cancer (MSS-CRC) remain expected in 1

GlobeNewswire 5 months ago

GRTS
-4.63%

Performance Overview

Return	GRTS	S&P 500
YTD	-62.00%	+5.55%
1-Year	-69.95%	+21.69%
3-Year	-91.58%	+20.44%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gritstone bio, Inc. (GRTS)

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

Gritstone bio Announces Proposed Public Offering

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

3 Speculative Stocks You Can Buy for $3 or Less

Gritstone bio, Inc. (NASDAQ:GRTS) Just Reported And Analysts Have Been Cutting Their Estimates

Gritstone bio Full Year 2023 Earnings: Beats Expectations

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Gritstone bio Announces Workforce Reduction

Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

Gritstone bio to Participate in Upcoming Investor Conference

Forecast: Analysts Think Gritstone bio, Inc.'s (NASDAQ:GRTS) Business Prospects Have Improved Drastically

Gritstone bio to Participate in Upcoming Investor Conferences

Gritstone Bio Inc (GRTS) Reports Q3 2023 Financial Results and Progress in Vaccine Development

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Performance Overview